Aripiprazole Intermediate CAS 129722-34-5 Purity >98.0% (HPLC)
Manufacturer Supply Intermediates of Aripiprazole With High Purity
Aripiprazole API CAS 129722-12-9
1-(2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2
7-Hydroxy-3,4-Dihydro-2(1H)-Quinolinone CAS 22246-18-0
7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone CAS 129722-34-5
| Chemical Name | 7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone |
| Synonyms | 7-(4-Bromobutoxy)-3,4-Dihydroquinolin-2(1H)-one; 7-(4-Bromobutoxy) -1,2,3,4-Tetrahydro-2-Oxoquinoline; 3,4-Dihydro-7-(4-Bromobutoxy)-2(1H)-Quinolinone; Aripiprazole Impurity 3 |
| CAS Number | 129722-34-5 |
| CAT Number | RF-PI2269 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C13H16BrNO2 |
| Molecular Weight | 298.18 |
| Density | 1.383 g/cm3 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Pale Yellow Crystal Powder |
| Purity / Analysis Method | >98.0% (HPLC) |
| Melting Point | 110.0~114.0℃ |
| Loss on Drying | <1.00% |
| Residue on Ignition | <0.50% |
| Heavy Metals (as Pb) | ≤20ppm |
| Proton NMR Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Aripiprazole (CAS: 129722-12-9) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone (CAS: 129722-34-5) is an intermediate in the synthesis of Aripiprazole (CAS: 129722-12-9). A degradation product in Aripiprazole tablets. Aripiprazole (Abilify). The newest, longactingaripiprazole (an arylpiperazine quinolinone derivative), appears to be partial agonist of D2 receptors (i.e., itstimulates certain D2 receptors while blocking others dependingon their locations in the brain and the concentrationof drug). Bioavailability of Aripiprazole is around 87%, with peak plasma concentration attained at 3 to 5 hours afterdosing. It is metabolized by dehydrogenation, oxidative hydroxylation, and N-dealkylation, largely mediated by hepatic CYPs 3A4 and 2D6. For the treatment of schizophrenia and related psychotic disorders. A selective dopamine D2-receptor antagonist with dopamine autoreceptor agonist activity. Antipsychotic.
